Review Article
Novel Immunotherapeutic Strategies of Gastric Cancer Treatment
Table 2
Major trials using anti-EGFR monoclonal antibodies.
| Treatment | Enrolled patients | Disease stage | Response rate | Time to progression | Overall survival | References |
| Cetuximab + Cis/CPT/RT | 5 EAC, 12 GEJAC | Locally advanced | 13% (2/15) | NS | NS | [62] | Cetuximab + Carbo/paclitaxel/RT | 45 EAC, 3 GAC, 12 SCC | Locally advanced | 27% (13/49) | NS | NS | [63] | Cetuximab + Cis/docetaxel/RT | 15 EAC/GEJAC, 13 SCC | Locally advanced | 32% (9/28) | NS | NS | [64] | Cetuximab + FOLFOX/RT | 9 AC, 18 SCC | Locally advanced | 40% (4/10) | NS | NS | [65] | Cetuximab/RT | 20 EAC 11 GEJAC, 9 SCC | Locally advanced | 36% (13/36) | NS | NS | [66] | Cetuximab/Cis/CPT + surgery + Cetuximab/5-FU/LV/RT | 20 GAC/GEJAC | Locally advanced | 0% (of 18) | NS | NS | [67] | Cetuximab + FOLFIRI | 4 GEJAC, 34 GAC | Metastatic (EGFR +ve) | 44% (of 34) | 8 months | 16 months | [68] | Cetuximab + FUFIRI | 15 GEJAC, 34 GAC | Metastatic | 42% (of 48) | 8.5 months | 16.6 months | [69] | Cetuximab + FUFOX | 25 GEJAC, 27 GAC | Metastatic | 65% (of 46) | 7.6 months | 9.5 months | [70] | Cetuximab + 5-FU/Cis verses 5-FU/Cis | 32 SCC 30 SCC | Metastatic | 19% 13% | 5.7 months 3.6 months | 9.5 months 5.5 months | [71] | Cetuximab + CI 5-FU/LV/Cis | 35 GAC | Metastatic | 69% | 11 months | 14.5 months | [72] | Cetuximab + Cis/docetaxel | 8 GEJAC, 40 GAC | Unresectable/meta static | 41% (of 42) | NS | NS | [73] | Cetuximab + oxaliplatin/CPT | 51 GAC | Metastatic | 63% (of 35) | 6.2 months | 9.5 months | [74] | Cetuximab | 55 EAC/GEJAC | Metastatic (2nd-line) | 2% | 1.8 months | 4 months | [75] | Cetuximab + Cis/CPT | 1 EAC, 7 GEJAC, 1 SCC | Metastatic (PD on Cis/CPT) | 11% | 1.3 months | NS | [76] | Cetuximab + docetaxel | 38 NS | Metastatic (PD on docetaxel) | 6% (of 35) | 2.1 months | 5.2 months | [77] | Cetuximab + CPT | 19 EAC/GEJAC, 8 GAC, 4 SCC | Metastatic (PD on platinum) | 6% | 3.2 months | NS | [78] | Matuzumab | 2 SCC | Metastatic (phase I) | 1 of 2 patients with 6-month partial response | [79] | Matuzumab + ECX | 5 EAC, 7 GEJAC, 9 GAC | Metastatic (phase I) | 65% (of 20) | 5.2 months | NS | [80] | Panitumumab | 3 NS | Metastatic (phase I) | 1 of 3 patients with 7-month stable disease | [81] |
|
|
5-FU: 5-fluorouracil; EAC: esophageal adenocarcinoma; Carbo: carboplatin; CI: continuous infusion; Cis: cisplatin; CPT: irinotecan; ECX: epirubicin/cisplatin/capecitabine; FOLFIRI: biweekly bolus 5-FU/leucovorin, irinotecan, infusional 5-FU; FUFIRI: weekly irinotecan/leucovorin/infusional; 5-FUFUFOX: weekly oxaliplatin/leucovorin/infusional 5-FU; LV: leucovorin; GAC: gastric adenocarcinoma; GEJAC: gastroesophageal junction adenocarcinoma; N/A: not applicable; NS: not stated; ORR: objective response rate; OS: overall survival; pCR: pathologic complete response; PD: progressive disease; RT: radiation therapy; SCC: squamous cell carcinoma; TTP: time-to-progression.
|